APOLLO: Short Interfering RNA Shows Promise for Reducing Lipoprotein(a) – American College of Cardiology -

A single ascending dose of SLN360, a short interfering RNA (siRNA), shows promise in lowering plasma lipoprotein(a) concentrations in patients with elevated lipoprotein(a) levels and no known cardiovascular disease, based on results from the phase 1 APOLLO trial presented April 3 at ACC.22 and simultaneously published in JAMA. The trial enrolled 32 people at five medical centers in the ...